Research Scientist, Stem Cell and Cancer Research Institute
905-525-9140 ext. 20543
Alternative RNA splicing is a crucial biological process to contribute to proteome diversity in eukaryotic cells. It has been shown in recent years that alternative splicing plays a decisive role in stem cell fate determination. Despite its significance, the fundamental regulatory mechanisms underlying alternative splicing remains unclear.
The Lu's laboratory intends to understand the alternative splicing regulatory mechanism using proteomics and systems biology. Novel proteomics and proteogenomics methods will be developed to profile splicing isoforms, to characterize splicing factors, and to identify signaling pathways that are responsible for individual alternative splicing events during directed differentiation in pluripotent human embryonic stem cells (ESC) and induced-pluripotent stem cells (iPSC).
These methods will be further applied to understand the alternative splicing regulation in terminal tissue differentiation to facilitate novel cell-based therapy development. Another application of these methods is to understand the alternative splicing regulation in cancer cells, with the purpose to provide novel insight in cancer treatment.